Stocks and Investing
Stocks and Investing
Thu, November 4, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gena Wang Maintained (BCRX) at Buy with Decreased Target to $17 on, Nov 4th, 2021
Gena Wang of Barclays, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Decreased Target from $21 to $17 on, Nov 4th, 2021.
Gena has made no other calls on BCRX in the last 4 months.
There are 4 other peers that have a rating on BCRX. Out of the 4 peers that are also analyzing BCRX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Maury Raycroft of "Jefferies" Downgraded from Strong Buy to Hold on, Friday, August 6th, 2021
These are the ratings of the 3 analyists that currently disagree with Gena
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $30 on, Friday, August 6th, 2021
- Jonathan Wolleben of "JMP Securities" Maintained at Buy with Increased Target to $23 on, Friday, August 6th, 2021
- Brian Cheng of "Cantor Fitzgerald" Initiated at Buy and Held Target at $21 on, Tuesday, August 3rd, 2021
Contributing Sources